Analysis reveals augmentation with aripiprazole may improve outcomes in treatment-resistant depression, highlighting potential side effects like weight gain and tardive dyskinesia.
Objective: In treatment-resistant depression (TRD), augmentation with aripiprazole (A-ARI) or combination therapy by adding bupropion (C-BUP) has been reported as more effective than switching to bupropion (S-BUP), but C-BUP risks falls in older adults, and A-ARI risks weight gain and tardive dyskinesia (TD). The aim of this study was to clarify whether the enhanced effectiveness outweighs such risks.
No takes yet. Share an insight, caveat, or question.
Meyerson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: